ASTEGIANO, MARCO
ASTEGIANO, MARCO
SCIENZE MEDICHE
Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn's disease: the extrapolation concept
2021-01-01 Ribaldone, Davide Giuseppe; Vernero, Marta; Astegiano, Marco
Efficacy of a preparation based on calcium butyrate, bifidobacterium bifidum, bifidobacterium lactis, and fructooligosaccharides in the prevention of relapse in ulcerative colitis: A prospective observational study
2021-01-01 Caviglia G.P.; De Blasio F.; Vernero M.; Armandi A.; Rosso C.; Saracco G.M.; Bugianesi E.; Astegiano M.; Ribaldone D.G.
Inflammatory bowel disease course in liver transplant versus non-liver transplant patients for primary sclerosing cholangitis: LIVIBD, an IG-IBD study
2021-01-01 Ribaldone D.G.; Imperatore N.; Le Grazie M.; Furfaro F.; Balestrieri P.; De Blasio F.; Fagoonee S.; Mosso E.; Boano V.; Reggio D.; Sarli E.; Castiglione F.; Milla M.; Vecchi M.; Saracco G.M.; Salizzoni M.; Romagnoli R.; Fiorino G.; Astegiano M.
Intestinal microbiota changes induced by TNF-inhibitors in IBD-related spondyloarthritis
2021-01-01 Ditto, Maria Chiara; Parisi, Simone; Landolfi, Gianpiero; Borrelli, Richard; Realmuto, Cristina; Finucci, Annacarla; Caviglia, Gian Paolo; Ribaldone, Davide Giuseppe; Astegiano, Marco; Zanetti, Anna; Carrara, Greta; Scirè, Carlo Alberto; Antivalle, Marco; Sarzi-Puttini, Piercarlo; Fusaro, Enrico
Late is too late? Surgical timing and postoperative complications after primary ileocolic resection for Crohn’s disease
2022-01-01 Lavorini E, Allaix ME, Ammirati CA, Astegiano M, Morino M, Resegotti A
RELATIONSHIP BETWEEN ADALIMUMAB, PHARMACOKINETICS AND VITAMIN D-RELATED MARKERS
2020-01-01 Mangia, M; Cusato, J; Ribaldone, DG; Astegiano, M; Saracco, GM; D'Avolio, A
Risk Factors of Urothelial Cancer in Inflammatory Bowel Disease
2021-01-01 Caviglia, Gian Paolo; Martini, Giorgio; Armandi, Angelo; Rosso, Chiara; Vernero, Marta; Bugianesi, Elisabetta; Astegiano, Marco; Saracco, Giorgio Maria; Ribaldone, Davide Giuseppe
Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn's Disease: A Prospective Study
2021-01-01 Ribaldone, Davide Giuseppe; Tribocco, Elisa; Rosso, Chiara; Armandi, Angelo; Vernero, Marta; Bugianesi, Elisabetta; Astegiano, Marco; Saracco, Giorgio Maria; Caviglia, Gian Paolo
Vitamin d-related genetics as predictive biomarker of clinical remission in adalimumab-treated patients affected by crohn’s disease: A pilot study
2021-01-01 Cusato J.; Bertani L.; Antonucci M.; Tomasello C.; Caviglia G.P.; Dibitetto S.; Massano A.; Mangia M.; Mula J.; Ceccarelli L.; Costa F.; Zanzi F.; Astegiano M.; Ribaldone D.G.; D'avolio A.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn's disease: the extrapolation concept | 2021 | Ribaldone, Davide Giuseppe; Vernero, Marta; Astegiano, Marco | |
| Efficacy of a preparation based on calcium butyrate, bifidobacterium bifidum, bifidobacterium lactis, and fructooligosaccharides in the prevention of relapse in ulcerative colitis: A prospective observational study | 2021 | Caviglia G.P.; De Blasio F.; Vernero M.; Armandi A.; Rosso C.; Saracco G.M.; Bugianesi E.; Astegiano M.; Ribaldone D.G. | |
| Inflammatory bowel disease course in liver transplant versus non-liver transplant patients for primary sclerosing cholangitis: LIVIBD, an IG-IBD study | 2021 | Ribaldone D.G.; Imperatore N.; Le Grazie M.; Furfaro F.; Balestrieri P.; De Blasio F.; Fagoonee S.; Mosso E.; Boano V.; Reggio D.; Sarli E.; Castiglione F.; Milla M.; Vecchi M.; Saracco G.M.; Salizzoni M.; Romagnoli R.; Fiorino G.; Astegiano M. | |
| Intestinal microbiota changes induced by TNF-inhibitors in IBD-related spondyloarthritis | 2021 | Ditto, Maria Chiara; Parisi, Simone; Landolfi, Gianpiero; Borrelli, Richard; Realmuto, Cristina; Finucci, Annacarla; Caviglia, Gian Paolo; Ribaldone, Davide Giuseppe; Astegiano, Marco; Zanetti, Anna; Carrara, Greta; Scirè, Carlo Alberto; Antivalle, Marco; Sarzi-Puttini, Piercarlo; Fusaro, Enrico | |
| Late is too late? Surgical timing and postoperative complications after primary ileocolic resection for Crohn’s disease | 2022 | Lavorini E, Allaix ME, Ammirati CA, Astegiano M, Morino M, Resegotti A | |
| RELATIONSHIP BETWEEN ADALIMUMAB, PHARMACOKINETICS AND VITAMIN D-RELATED MARKERS | 2020 | Mangia, M; Cusato, J; Ribaldone, DG; Astegiano, M; Saracco, GM; D'Avolio, A | |
| Risk Factors of Urothelial Cancer in Inflammatory Bowel Disease | 2021 | Caviglia, Gian Paolo; Martini, Giorgio; Armandi, Angelo; Rosso, Chiara; Vernero, Marta; Bugianesi, Elisabetta; Astegiano, Marco; Saracco, Giorgio Maria; Ribaldone, Davide Giuseppe | |
| Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn's Disease: A Prospective Study | 2021 | Ribaldone, Davide Giuseppe; Tribocco, Elisa; Rosso, Chiara; Armandi, Angelo; Vernero, Marta; Bugianesi, Elisabetta; Astegiano, Marco; Saracco, Giorgio Maria; Caviglia, Gian Paolo | |
| Vitamin d-related genetics as predictive biomarker of clinical remission in adalimumab-treated patients affected by crohn’s disease: A pilot study | 2021 | Cusato J.; Bertani L.; Antonucci M.; Tomasello C.; Caviglia G.P.; Dibitetto S.; Massano A.; Mangia M.; Mula J.; Ceccarelli L.; Costa F.; Zanzi F.; Astegiano M.; Ribaldone D.G.; D'avolio A. |